上海毕得医药科技股份有限公司 防范控股股东及其关联方资金占用制度 第一条 根据《中华人民共和国公司法》、《中华人民共和国证券法》等有关 法律、行政法规、部门规章、规范性文件的要求以及《上海毕得医药科技股份有 限公司章程》的有关规定，为了建立上海毕得医药科技股份有限公司(以下简称 "公司")防范控股股东及其他关联方占用公司资金的长效机制，杜绝控股股东 及其他关联方资金占用行为的发生，特制定本制度。 第二条 公司董事、高级管理人员对维护公司资金安全负有法定义务。 第三条 本制度所称资金占用包括但不限于：经营性资金占用和非经营性资 金占用。经营性资金占用是指控股股东及其他关联方与公司发生的经营性资产往 来中，违反公司资金管理规定，直接或变相占用公司资金逾期不还；非经营性资 金占用是指代控股股东及其他关联方垫付工资、福利、保险、广告等费用和其他 支出，代控股股东及其他关联方偿还债务而支付的资金，有偿或无偿直接或间接 拆借给控股股东及其他关联方的资金，为控股股东及其他关联方承担担保责任而 形成的债权，其他在没有商品和劳务对价情况下给控股股东及其他关联方使用的 资金。 第四条 公司要严格防止控股股东及其他关联方的非经营性 ...

上海毕得医药科技股份有限公司 董事会议事规则 第一章 总 则 第一条 为明确公司董事会的职责权限，规范公司董事会的议事方式和决策 程序，促使公司董事和董事会有效地履行职责，提高公司董事会规范运作和科学 决策水平，根据《中华人民共和国公司法》 第三条 公司董事会的组成由公司章程作出规定。 第四条 董事会在《公司法》和公司章程规定的范围内依法行使职权。 第五条 公司董事为自然人，有下列情形之一的，不能担任公司的董事： （以下简称"《公司法》"）、 《中华人民 共和国证券法》、《上市公司章程指引》、《上海证券交易所科创板股票上市规则》 （以下简称"《股票上市规则》"）、《上市公司治理准则》及《上海毕得医药科技 股份有限公司章程》（以下简称"公司章程"）等有关规定，制定本规则。 第二章 董事会的组成和职权 第二条 公司依法设立董事会。 （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩序， 被判处刑罚，或者因犯罪被剥夺政治权利，执行期满未逾 5 年，被宣告缓刑的， 自缓刑考验期满之日起未逾 2 年； （三）担任破产清算的公司、企业的董事或者厂长、经理，对该公司 ...

Core Viewpoint - Tianyu Co., Ltd. (300702) expects a significant increase in net profit for the first half of 2025, projecting a profit of between 130 million to 180 million yuan, representing a growth of 144.29% to 238.25% compared to the same period last year [1] Financial Performance - The net profit attributable to shareholders is projected to be between 130 million to 180 million yuan, compared to 53.2152 million yuan in the same period last year [1] - The net profit after deducting non-recurring gains and losses is expected to be between 121 million to 171 million yuan, an increase from 62.764 million yuan year-on-year, reflecting a growth of 92.79% to 172.45% [1] Growth Drivers - The company's performance growth is driven by actively seizing market opportunities, expanding customer channels, and enhancing refined management [1] - Measures such as optimizing product structure, improving market layout, and strengthening cost control have effectively increased revenue and gross profit in non-sartans raw materials and intermediates, CDMO business, and formulation business [1]

诚意药业 20250714 Q&A 请介绍诚意药业 2024 年到 2025 年上半年的经营情况。 诚意药业在 2024 年的整体营收和利润表现良好，全年营收超过七亿元，利润 突破两亿元。主要得益于氨糖销售的快速增长，2024 年氨糖销售额约五亿元， 同比增长超过 20%，其中医院端的增长尤为显著，达到一倍以上。2025 年上 半年，这一增长趋势继续保持强劲。公司在国采到期后转为省地方性联采模式， 从原先中标九个省份扩展到三十多个省份，有效提升了医院端的销售量，同时 公司调整鱼油保健品业务，由董事长女儿接管，计划投入预算到小红书 等平台，开展市场调研。鱼油产品预计 2025 年第三季度上市，计划与 其他大型药厂合作，争取合理的国产价格，并考虑与他汀类药物联用， 降低心血管疾病风险。 高纯度 EPA 原料药 DMF 申报遇到问题，预计最早 2026 年上半年完成。 公司关注欧洲、美洲和东南亚市场，按 300 吨计算，原料端利润率约为 50%。福建华康转型为医药企业后扭亏为盈，预计 2025 年利润将超过 1,000 万元。 公司发布员工持股计划，设定未来三年业绩指标，2025 年目标是利润 增长 35%。公司预 ...

Group 1 - The company has approved the use of idle raised funds for cash management, allowing up to RMB 1.2 billion to be invested in high-security, liquid financial products [1] - The investment products include structured deposits, time deposits, large certificates of deposit, notice deposits, income certificates, and wealth management products from banks or brokers, with a maximum investment period of 12 months [1] - The company redeemed part of the cash management products and returned the funds to the designated account, with the Agricultural Bank of China cash management sub-account being automatically canceled after redemption [2] Group 2 - As of the announcement date, the company has used idle raised funds for cash management within the approved amount and time frame, and has informed the sponsor institution of the redemption status [2] - The company utilized RMB 935 million of idle raised funds to purchase cash management products issued by financial institutions between January 13 and January 14, 2025 [2]

海南双成药业股份有限公司 关于召开2025年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 海南双成药业股份有限公司（以下简称"公司"）第五届董事会第十九次会 议于 2025 年 7 月 14 日召开，会议定于 2025 年 7 月 31 日（星期四）召开 2025 年第一次临时股东会，现将本次股东会的有关事项通知如下： 一、召开会议的基本情况 决定召开股东会，本次股东会的召集程序符合法律、法规、规范性文件和《公司 章程》的规定。 网络投票时间：2025 年 7 月 31 日 （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 7 月 31 日 9:15-9:25，9:30-11:30 和 13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的时间为 2025 年 7 月 31 日 公司股东应选择现场投票、网络投票中的一种方式，如果同一表决权出现重复投 票表决的，以第一次投票表决结果为准。 证券代码：002693 证券简称：*ST双成 公告编号：2025-046 （1）截至 2025 年 7 月 25 ...

一、担保情况概述 证券代码：002693 证券简称：*ST双成 公告编号：2025-045 海南双成药业股份有限公司 关于为控股子公司提供担保暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 公司本次提供担保的对象为合并报表范围内的控股子公司，其最近一期经审 计的资产负债率超过 70%，但其经营状况良好，公司能够全面掌控其运行，担保 风险可控。特此提醒投资者充分关注担保风险。 海南双成药业股份有限公司（以下简称"公司"）控股子公司宁波双成药业 有限公司（以下简称"宁波双成"）因日常经营需要，拟向中国建设银行股份有 限公司宁波杭州湾新区支行（以下简称"建设银行"）申请 4,000 万元借款，借 款期限至 2028 年 7 月 31 日。公司和公司控股股东海南双成投资有限公司（以下 简称"双成投资"）拟为宁波双成向建设银行借款分别提供连带责任担保，担保 期限为主合同下的债务履行期届满之日起三年。 双成投资为公司控股股东，同时持有宁波双成 48.81%的股份。根据《深圳 证券交易所股票上市规则》等相关规定，本次对外提供担保构成关联交易 ...

Core Viewpoint - The first half of 2025 financial reports from A-share listed companies reveal significant profit increases, with several companies projecting profit growth exceeding tenfold compared to the previous year [1][5]. Group 1: Company Performance - Zhongyan Chemical's 2025 half-year report shows a revenue of 5.998 billion yuan, a decrease of 5.76% year-on-year, with a net profit of 52.7155 million yuan, down 88.04% year-on-year [3][4]. - The decline in Zhongyan Chemical's revenue is attributed to intensified market competition and significant price drops in key products like soda ash and PVC, despite a 38.82% increase in sales volume [3][4]. - Huahong Technology expects a net profit of 70 million to 85 million yuan for the first half of 2025, representing a year-on-year increase of 3047.48% to 3721.94%, driven by improved prices of rare earth raw materials [6][7]. - Wannianqing anticipates a net profit of 31 million to 45 million yuan, reflecting a year-on-year growth of 1954.07% to 2881.71%, supported by recovering demand in the cement industry and cost reduction efforts [6][7]. - Other companies like Yatai Pharmaceutical and Aerospace Science and Technology also project substantial profit increases, with expected growth rates of 1726.42% to 1909.06% and 1628.83% to 2315.27%, respectively [7]. Group 2: Market Trends - The overall trend indicates a recovery in certain sectors, such as the cement industry, due to reduced declines in real estate investment and infrastructure spending [7]. - The chemical industry is experiencing price fluctuations, with some products seeing significant price drops due to weakened downstream demand, while others like caustic soda have increased prices due to demand pull [4].

Group 1 - The core project is the flexible production line renovation project for synthetic biology at Zhejiang Haizheng Pharmaceutical Co., Ltd., with a total investment of 171.06 million yuan, including 5.1 million yuan for environmental protection [2][4]. - The project aims to produce 72,000 tons of 60% liquid glucose, 93,816 tons of 30% liquid glucose, 1,500 tons of yeast, and various other products annually, including 2,000 tons of HS31101 sulfate and 1,000 tons of HS31101 hydrochloride [2][3]. - The project will utilize existing production lines in the Y108, Y109, Y110, Y112, and Y27 workshops at the Yantou plant [2][3]. Group 2 - The fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held in Ningbo, Zhejiang, from August 20 to 22, focusing on five key areas: AI + biological manufacturing, green chemicals and new materials, future food, future agriculture, and beauty raw materials [5][6]. - The conference aims to explore the development trends of the bio-manufacturing industry during the 14th Five-Year Plan and discuss innovative technologies and products that will sustain the industry [5].

Core Viewpoint - Dezheng Health (000813) expects a net profit loss of 25 million to 50 million yuan in the first half of 2025, compared to a profit of 10.15 million yuan in the same period last year, representing a year-on-year decline of 346.24% to 592.48% [1] Financial Summary - The projected net profit loss for the first half of 2025 is between 25 million and 50 million yuan [1] - The profit for the same period last year was 10.15 million yuan [1] - The year-on-year decline in net profit is estimated to be between 346.24% and 592.48% [1]